On Nov. 15, 2022, Roche announced that the U.S. Food and Drug Administration had granted Emergency Use Authorization for cobasﾮ MPXV for use on the cobasﾮ 6800/8800 Systems. The test is a real time PCR test for the qualitative detection of DNA from monkeypox virus (MPXV) in lesion swabs collected from individuals suspected of monkeypox infection by their healthcare provider.